Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atazanavir; Atazanavir/ritonavir; Efavirenz; Emtricitabine; Lopinavir/ritonavir; Ritonavir; Tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms ADVANZ-3

22 Feb 2013 Biomarkers information updated
01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
20 Jul 2011 Results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com